Why the study?
Does PAR4 inhibition with BMS-986120 provide effective antithrombotic activity with low bleeding risk compared to clopidogrel in preclinical models?
Population
Preclinical models (guinea pigs and cynomolgus monkey arterial thrombosis model)
Comparison
PAR4 inhibition vs Clopidogrel (in the nonhuman primate model)
Design
Preclinical
Authors
Loading...
Supports PAR4 inhibition for further development; leaves open translation to human antithrombotic therapy.
Does PAR4 inhibition with BMS-986120 provide effective antithrombotic activity with low bleeding risk compared to clopidogrel in preclinical models?
Targeting PAR4 with the novel antagonist BMS-986120 provides robust antithrombotic efficacy with a lower bleeding risk than clopidogrel in preclinical models.
Wong et al. (2017) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: